Cai Jing Wang·2026-02-09 04:12Core Insights - The core viewpoint of the article is the strategic collaboration between Innovent Biologics and Eli Lilly to advance the global development of innovative drugs in oncology and immunology, marking their seventh partnership and strengthening their long-term relationship [1] Group 1: Partnership Details - The agreement allows both companies to leverage their complementary strengths to accelerate the global R&D of innovative drugs [1] - Innovent Biologics will lead the projects from drug discovery to clinical proof of concept in China, specifically completing Phase II clinical trials [1] - Eli Lilly will obtain exclusive development and commercialization rights outside Greater China, while Innovent retains all rights within Greater China [1] Group 2: Financial Aspects - Innovent Biologics will receive an upfront payment of $350 million [1] - Upon achieving specific milestones, Innovent is eligible for up to approximately $8.5 billion in milestone payments related to R&D, regulatory, and commercialization [1] - Innovent will also have the right to receive a tiered sales share based on net sales outside Greater China for each product [1]